Neuroprotection in Huntington's disease

被引：0

作者：

Bonelli, RM ^{[1
]}

Hödl, AK ^{[1
]}

Kapfhammer, HP ^{[1
]}

机构：

[1] Graz Med Univ, Univ Clin Psychiat, A-8036 Graz, Austria

来源：

LETTERS IN DRUG DESIGN & DISCOVERY | 2005年 / 2卷 / 02期

关键词：

D O I：

10.2174/1570180053175133

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Minocycline, the 7-dimethylamino- 6-dimethyl-desoxytetracycline hydrochloride, is a caspase-1 inhibitor and may serve as anti-apoptotic agent, thereby acting neuroprotective. It directly inhibits both caspase-independent and -dependent mitochondrial cell death pathways, and decreases inducible nitric oxide synthetase activity. Minocycline delays disease progression in the transgenic mouse model of Huntington's disease (HD), extending survival by 14%. HD is a late onset relentlessly progressive, neurodegenerative disorder with currently no cures or even effective therapies, death occurring 15 years after onset. In this review, recent clinical and preclinical data on minocycline in HD and neuroprotective alternatives discussed.

引用

页码：143 / 147

页数：5

共 50 条

[21] Dose dependent neuroprotection of VEGF165 in Huntington's disease striatum [J].

Ellison, Stuart ;

Trabalza, Antonio ;

Tisato, Veronica ;

Pazarentzos, Evangelos ;

Lee, Shirley ;

Papadaki, Vasiliki ;

Goniotaki, Despoina ;

Morgan, Sarah ;

Mirzaei, Nazanin ;

Mazarakis, Nicholas .

HUMAN GENE THERAPY, 2013, 24 (05) :A8-A8

[22] PINK1-induced mitophagy promotes neuroprotection in Huntington's disease [J].

Khalil, B. ;

El Fissi, N. ;

Aouane, A. ;

Cabirol-Pol, M-J ;

Rival, T. ;

Lievens, J-C .

CELL DEATH & DISEASE, 2015, 6 :e1617-e1617

[23] PINK1-induced mitophagy promotes neuroprotection in Huntington’s disease [J].

B Khalil ;

N El Fissi ;

A Aouane ;

M-J Cabirol-Pol ;

T Rival ;

J-C Liévens .

Cell Death & Disease, 2015, 6 :e1617-e1617

[24] Cellular delivery of trophic factors for the treatment of Huntington's disease: Is neuroprotection possible? [J].

Kordower, JH ;

Isacson, O ;

Emerich, DF .

EXPERIMENTAL NEUROLOGY, 1999, 159 (01) :4-20

[25] Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease [J].

Sarantos, Melissa R. ;

Papanikolaou, Theodora ;

Ellerby, Lisa M. ;

Hughes, Robert E. .

JOURNAL OF HUNTINGTONS DISEASE, 2012, 1 (02) :195-210

[26] Dose-dependent Neuroprotection of VEGF165 in Huntington's Disease Striatum [J].

Ellison, Stuart M. ;

Trabalza, Antonio ;

Tisato, Veronica ;

Pazarentzos, Evangelos ;

Lee, Shirley ;

Papadaki, Vasiliki ;

Goniotaki, Despoina ;

Morgan, Sarah ;

Mirzaei, Nazanin ;

Mazarakis, Nicholas D. .

MOLECULAR THERAPY, 2013, 21 (10) :1862-1875

[27] TRAX Provides Neuroprotection for Huntington's Disease Via Modulating a Novel Subset of MicroRNAs [J].

Weng, Yu-Ting ;

Chen, Hui-Mei ;

Chien, Ting ;

Chiu, Feng-Lan ;

Kuo, Hung-Chih ;

Chern, Yijuang .

MOVEMENT DISORDERS, 2022, 37 (10) :2008-2020

[28] Huntington's disease: Neuropsychiatric manifestations of Huntington's disease [J].

Goh, Anita M. Y. ;

Wibawa, Pierre ;

Loi, Samantha M. ;

Walterfang, Mark ;

Velakoulis, Dennis ;

Looi, Jeffrey C. L. .

AUSTRALASIAN PSYCHIATRY, 2018, 26 (04) :366-375

[29] Stuck in the Middle: Huntington's Disease or not Huntington's Disease? [J].

Ziso, Besa ;

Larner, Andrew J. ;

Alusi, Sundus H. .

JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES, 2015, 27 (01) :E85-E86

[30] Huntington's disease: Brain imaging in Huntington's disease [J].

Johnson, Eileanoir B. ;

Gregory, Sarah .

BRAIN IMAGING, 2019, 165 :321-369

← 1 2 3 4 5 →